LGND

#1394
Ligand Pharmaceuticals Inc.
231.2650 USD
+8.35%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
225.8000
231.4350
Rango anual
175.8900
231.4350
Cambio diario
+8.35%
Variación mensual
+13.20%
Variación en los últimos 6 meses
+23.59%
Cambio anual
+23.59%
Cierres anteriores
213.4400
Abrir
230.0000
Bid
Ask
Mínimo
225.8000
High
231.4350
Volumen
91
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
  • Market Capitalization 4.6117 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
30.84
Relación precio/flujo de caja
14.31
Dividendos por acción
2.5
Rendimiento por dividendo, %
1.32

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Noticias